The Guardian - Pharmaceutical Industry

JANUARY 14, 2024

Unpublished figures reveal a doubling of products in short supply over past two years ‘The worst I’ve known it’: the struggle to get vital medicines Analysis: why is UK being hit by medicine supply shortages? An unprecedented medicines shortage in the NHS is endangering lives, pharmacists have said, as unpublished figures reveal that the number of products in short supply has doubled in two years.

111

111

pharmaphorum

JANUARY 14, 2024

FDA has opened a comment period until January 31 on how digital health technologies (DHTs) may be deployed to help prevent, detect and manage diabetes

FDA 104

FDA 104

The Guardian - Pharmaceutical Industry

JANUARY 14, 2024

Four people with conditions that require consistent medication explain how the shortages have affected their wellbeing NHS medicines shortage putting people at risk, pharmacists warn Analysis: why is UK being hit by medicine supply shortages? More people in the UK are struggling to access vital medicines than ever before, exacerbating conditions from epilepsy to the menopause.

94

94

Med Ed 101

JANUARY 14, 2024

Fenofibrate is a lipid-lowering medication indicated as monotherapy to treat primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. While this medication has been around for many years, its formulation has continued to evolve. The different fenofibrate formulations can get confusing, especially when terms such as micronized, nanoparticles, and solid dispersions get thrown into the mix.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development.

Immunization 40

Immunization Vaccines FDA 40